Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/20 | $5,000,000 | Series A |
Burns & Stowers Investments i2E  Mayo Clinic Ventures NMC OCA Venture Partners Oklahoma Medical Research Foundation Oklahoma Seed Capital Fund Plains Venture Partners Stanford University | undisclosed |
